威海百合生物技术股份有限公司关于职工代表大会选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》及中国证监会《关于新〈公司法〉配套制度规则实施相关过渡期安排》 的相关规定，威海百合生物技术股份有限公司（以下简称"公司"）于2025年9月26日召开2025年第一次 临时股东大会，审议通过了《关于取消监事会及修订公司章程的议案》，本次章程修订包括不再设置监 事会或监事、在董事会中增设职工代表董事职位等事项。故公司于2025年9月26 日召开职工代表大会， 经会议选举通过，一致同意姚建伟先生担任公司职工代表董事，任期自本次职工代表大会审议通过之日 起至公司第四届董事会任期届满之日止。姚建伟先生简历详见附件。 证券代码：603102 证券简称：百合股份 公告编号：2025-038 鉴于姚建伟先生原已担任公司董事，故公司第四届董事会成员保持不变。截至本公告披露日，姚建伟先 生持有公司股份109,875股，除已披露的任职外，其与其他持有公司5%以上股份的股东、其他董事和高 级管理人员不存在关 ...

威海百合生物技术股份有限公司董事会 2025 年 9 月 27 日 证券代码：603102 证券简称：百合股份 公告编号：2025-038 威海百合生物技术股份有限公司 关于职工代表大会选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》及中国证监会《关于新<公司法>配套制度规 则实施相关过渡期安排》的相关规定，威海百合生物技术股份有限公司（以下简 称"公司"）于 2025 年 9 月 26 日召开 2025 年第一次临时股东大会，审议通过 了《关于取消监事会及修订公司章程的议案》，本次章程修订包括不再设置监事 会或监事、在董事会中增设职工代表董事职位等事项。故公司于 2025 年 9 月 26 日召开职工代表大会，经会议选举通过，一致同意姚建伟先生担任公司职工代表 董事，任期自本次职工代表大会审议通过之日起至公司第四届董事会任期届满之 日止。姚建伟先生简历详见附件。 鉴于姚建伟先生原已担任公司董事，故公司第四届董事会成员保持不变。截 至本公告披露日，姚建伟先生持有公司股份 10 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-037 威海百合生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 26 日 (二)股东大会召开的地点：山东省威海市荣成市荣义路 2899 号公司研发大楼四 楼会议室 本次股东大会由公司董事会召集，本次会议现场由董事刘旭东先生主持，采用现 场与网络投票相结合的方式召开。本次会议的召集、召开和表决方式符合《公司 法》等法律法规和《公司章程》的有关规定。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 64 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 35,601,215 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 57.1688 | 注： ...

. 2 PM w Offices 北京市东城区金宝街 89 号金宝大厦 11 层 11F Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing, China 电话(Tel):(86 10)6652 3388 传真(Fax):(86 10)6652 3399 网址(Website): www.junzejun.com 北京市君泽君律师事务所 关于威海百合生物技术股份有限公司 致:威海百合生物技术股份有限公司 威海百合生物技术股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会(以下简称"本次股东大会")于 2025年 9 月 26 日召开,北京市君泽 君律师事务所(以下简称"本所")接受公司的委托,就公司本次股东大会的相 关事宜出具法律意见。 本所及经办律师依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》《律师事务所从事证券法律业务管理办法》和《律师事 务所证券法律业务执业规则(试行)》等规定及本法律意见出具日以前已经发生 或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进行 了充分的核查 ...

Core Insights - The food processing sector experienced a slight decline of 0.16% on September 24, with Weizhi Xiang leading the drop [1][2] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Stock Performance - Notable gainers in the food processing sector included: - Baba Foods (605338) with a closing price of 23.57, up 4.90% [1] - Guangming Meat (600073) at 7.05, up 2.47% [1] - ST Chuntian (600381) at 5.19, up 2.37% [1] - Conversely, Weizhi Xiang (605089) closed at 28.11, down 1.54% [2] - The sector saw a total trading volume of 5.67 billion yuan in net outflow from major funds, while retail investors contributed a net inflow of 2.49 billion yuan [2][3] Fund Flow Analysis - Major funds showed a net outflow of 5.67 billion yuan, while speculative funds had a net inflow of 3.18 billion yuan [2] - Retail investors contributed a net inflow of 2.49 billion yuan [2] - Specific stock fund flows included: - Guangming Meat (600073) with a net inflow of 17.05 million yuan from major funds [3] - Jindawi (002626) with a net inflow of 11.20 million yuan from major funds [3] - Xianle Health (300791) had a net inflow of 2.03 million yuan from retail investors [3]

Group 1 - The core viewpoint of the report is that the functional food industry in China is undergoing a significant transformation driven by rising health awareness and changing consumer demands, leading to accelerated market penetration across all age groups [1][2][11]. - The functional food market in China has experienced a compound annual growth rate (CAGR) of 6.3% over the past five years, significantly outpacing the growth of other basic consumer goods, with the market size expected to exceed 260 billion yuan in 2024 and potentially double to around 450 billion yuan in the next decade [2][22][20]. - The demand for functional foods is shifting from a focus on basic health benefits to a broader appeal that includes emotional satisfaction and lifestyle enhancement, with a diverse range of products catering to various demographics, including women, youth, and even pets [3][27][28]. Group 2 - The growth of the functional food industry is supported by multiple factors, including economic stability, rising disposable income, and an aging population, which has led to increased health consciousness among consumers [2][20][11]. - The online sales channel for functional foods has surged, accounting for over 55% of total sales, with platforms like Douyin (TikTok) and cross-border e-commerce showing remarkable growth, indicating a shift towards digital and diversified sales strategies [5][11][12]. - The industry is characterized by a dual structure of established leading brands maintaining stable market shares while new, agile brands rapidly emerge by capturing niche demands, resulting in a long-tail market trend [6][12][11]. Group 3 - Innovations in product forms and consumer experiences are crucial, with a rise in "snack-like" products such as gummies and beverages that appeal to younger consumers, enhancing the overall consumption experience [4][33][38]. - Marketing strategies are evolving to emphasize emotional resonance and lifestyle alignment, with brands focusing on customized nutrition solutions and appealing packaging to attract younger demographics [4][38][39]. - The report highlights the importance of understanding the changing dynamics in both consumer preferences and distribution channels, suggesting that brands must adapt to these trends to thrive in the competitive landscape [5][12][11].

证券之星消息，9月15日食品加工板块较上一交易日上涨0.49%，得利斯领涨。当日上证指数报收于 3860.5，下跌0.26%。深证成指报收于13005.77，上涨0.63%。食品加工板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002330 | 得利斯 | 5.45 | 10.10% | 37.72万 | | 2.06亿 | | 002726 | 龙大美食 | 6.13 | 5.69% | 121.16万 | | 7.41亿 | | 603536 | 惠发食品 | 11.40 | 5.56% | 46.78万 | | 5.42亿 | | 605089 | 味知香 | 28.50 | 4.93% | 8.31万 | | 2.39亿 | | 002840 | 华统股份 | 12.26 | 4.88% | 43.25万 | | 5.21亿 | | 001215 | 千味央厨 | 34.92 | 3.96% | 10.47万 | | 3.65亿 | | 60310 ...

威海百合生物技术股份有限公司 2025 年第一次临时股东大会 会议材料 2025 年 9 月 26 日 威海百合生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证股 东大会的顺利召开，根据《公司法》《上市公司股东会规则》及《公司章程》的 有关规定，特制定如下会议须知，望出席股东大会的全体人员遵照执行。 一、为保证股东大会的严肃性和正常秩序，切实维护与会股东（或股东授权 代表）的合法权益，公司认真做好召开股东大会的各项工作。 二、除出席会议的股东（或股东授权代表）、公司董事、监事、高级管理人 员、公司聘请的律师、董事会邀请的人员及相关工作人员外，公司有权依法拒绝 其他人进入会场。 三、股东参加股东大会，应当认真履行其法定义务，会议开始后应将手机铃 声置于无声状态，尊重和维护其他股东合法权益，保障大会的正常秩序。 四、股东参加股东大会依法享有表决权、发言权、质询权等权利。 五、股东需要发言的，需先经会议主持人许可，方可发言。股东发言时应首 先报告姓名（或所代表股东）及持有股份数额。每一股东发言不得超过两次，每 次发言原则上不超过 5 分钟 ...

Market Overview - On September 5, the food processing sector rose by 0.68% compared to the previous trading day, with Baihe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Baihe Co., Ltd. (603102) closed at 46.51, with a significant increase of 10.00% and a trading volume of 35,200 hands, amounting to a transaction value of 160 million yuan [1] - Other notable performers included Kangbiter (833429) with a 4.39% increase, and Tangchen Beijian (300146) with a 2.26% increase [1] Capital Flow - The food processing sector experienced a net outflow of 48.96 million yuan from institutional investors, while retail investors saw a net outflow of 83.72 million yuan [2] - Conversely, speculative funds recorded a net inflow of 133 million yuan [2] Individual Stock Capital Flow - Baihe Co., Ltd. had a net inflow of 42.73 million yuan from institutional investors, but a net outflow of 20.46 million yuan from retail investors [3] - Guangming Meat Industry (600073) also saw a net inflow of 23.86 million yuan from institutional investors, with retail investors experiencing a net outflow of 20.24 million yuan [3]

Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the industry index by over 15% in the next six months [5][18]. Core Views - The company is undergoing a strategic transformation that is causing short-term pressure but is expected to empower long-term development through cross-border mergers and acquisitions [1][4]. - The company has a strong presence in the nutritional health product industry, with nearly 20 years of R&D and production experience, and offers comprehensive contract manufacturing services [4]. Financial Performance Summary - For 2023A, the company reported revenue of 871 million yuan, with a projected revenue of 801 million yuan for 2024A, followed by 944 million yuan in 2025E, 1,421 million yuan in 2026E, and 1,687 million yuan in 2027E [1][10]. - The year-on-year growth rates for revenue are projected to be 20.1% for 2023A, -8.0% for 2024A, 17.8% for 2025E, 50.4% for 2026E, and 18.8% for 2027E [1][10]. - The net profit attributable to the parent company is expected to decrease from 169 million yuan in 2023A to 139 million yuan in 2024A, before recovering to 152 million yuan in 2025E, 205 million yuan in 2026E, and 245 million yuan in 2027E [1][10]. - The company’s return on equity (ROE) is projected to decline from 11.2% in 2023A to 8.7% in 2024A, before gradually increasing to 12.5% by 2027E [1][10]. Business Segment Performance - In the first half of 2025, the company achieved revenue of 420 million yuan, with a year-on-year growth of 2.06%. The contract manufacturing segment showed resilience with a revenue of 366 million yuan, up 10.71% year-on-year, while the self-owned brand segment saw a decline of 33.61% [2][3]. - The company launched a new brand, focusing on a strategic shift towards scientifically-based health products, aiming to build a unique nutritional health system for Asian consumers over the next decade [2]. Cost and Investment Insights - The company is increasing its costs and investments for transformation, which has led to a short-term pressure on profits. The gross margin and net profit margin for the first half of 2025 were 36.22% and 17.10%, respectively, both showing a decline compared to the previous year [3]. - Operating cash flow for the first half of 2025 was 74 million yuan, reflecting a year-on-year increase of 14.02%, indicating a stable operational condition [3]. Mergers and Acquisitions - The company completed a cross-border acquisition of 56% of Ora for 67 million yuan, which is expected to enhance its overseas supply chain and accelerate international expansion [4]. Ora reported a revenue of 42.28 million New Zealand dollars in 2024, with a significant year-on-year growth of 102.34% [4].